Vanguard Group
STRO icon

Vanguard Group’s Sutro Biopharma STRO Stock Holding History

Vanguard Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.35M Buy
375,786
+7,487
+2% +$71K ﹤0.01% 3308
2025
Q3 		$3.2M Sell
368,299
-43,226
-11% -$368K ﹤0.01% 3424
2025
Q2 		$2.94M Sell
411,525
-27,999
-6% -$229K ﹤0.01% 3391
2025
Q1 		$2.86M Buy
439,524
+18,674
+4% +$294K ﹤0.01% 3365
2024
Q4 		$7.74M Buy
420,850
+1,343
+0.3% +$41K ﹤0.01% 3078
2024
Q3 		$14.5M Buy
419,507
+63,973
+18% +$2.51M ﹤0.01% 2766
2024
Q2 		$10.4M Buy
355,534
+53,255
+18% +$2.11M ﹤0.01% 2892
2024
Q1 		$17.1M Buy
302,279
+13,279
+5% +$587K ﹤0.01% 2679
2023
Q4 		$12.4M Buy
289,000
+2,124
+0.7% +$67.4K ﹤0.01% 2831
2023
Q3 		$9.95M Buy
286,876
+3,885
+1% +$169K ﹤0.01% 2880
2023
Q2 		$13.2M Buy
282,991
+5,295
+2% +$264K ﹤0.01% 2794
2023
Q1 		$12.8M Buy
277,696
+13,229
+5% +$840K ﹤0.01% 2804
2022
Q4 		$21.4M Buy
264,467
+59,439
+29% +$4.13M ﹤0.01% 2593
2022
Q3 		$11.4M Buy
205,028
+1,295
+0.6% +$76.6K ﹤0.01% 2896
2022
Q2 		$10.6M Sell
203,733
-19,367
-9% -$1.08M ﹤0.01% 2963
2022
Q1 		$18.3M Buy
223,100
+11,319
+5% +$1.08M ﹤0.01% 2825
2021
Q4 		$31.5M Buy
211,781
+278
+0.1% +$49.8K ﹤0.01% 2613
2021
Q3 		$40M Buy
211,503
+5,183
+3% +$985K ﹤0.01% 2485
2021
Q2 		$38.4M Buy
206,320
+2,321
+1% +$454K ﹤0.01% 2509
2021
Q1 		$46.4M Buy
203,999
+11,637
+6% +$2.76M ﹤0.01% 2360
2020
Q4 		$41.8M Buy
192,362
+62,381
+48% +$10.3M ﹤0.01% 2295
2020
Q3 		$13.1M Buy
129,981
+30,084
+30% +$2.84M ﹤0.01% 2656
2020
Q2 		$7.75M Buy
99,897
+62,079
+164% +$5.96M ﹤0.01% 2890
2020
Q1 		$3.86M Buy
37,818
+3,759
+11% +$395K ﹤0.01% 3079
2019
Q4 		$3.75M Buy
34,059
+1,729
+5% +$178K ﹤0.01% 3264
2019
Q3 		$2.94M Buy
32,330
+12,805
+66% +$1.29M ﹤0.01% 3316
2019
Q2 		$2.22M Buy
19,525
+1,848
+10% +$204K ﹤0.01% 3447
2019
Q1 		$2.01M Buy
17,677
+5,249
+42% +$546K ﹤0.01% 3448
2018
Q4 		$1.12M Buy
+12,428
New +$1.5M ﹤0.01% 3535

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group's STRO Position: Q4 2025 in Review

Vanguard Group increased its Sutro Biopharma (STRO) stake by 2% in Q4 2025, buying an estimated $71K and bringing the position to 375,786 shares worth $4.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3308.

Vanguard Group first reported a position in STRO in Q4 2018 and has held it in 29 quarters since. The position peaked at $46.4M in Q1 2021. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Vanguard Group held 375,786 shares of Sutro Biopharma worth $4.35M as of Q4 2025.
  • Vanguard Group bought 7,487 Sutro Biopharma shares in Q4 2025, an estimated $71K.
  • Sutro Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3308 holding.
  • Vanguard Group first reported a position in Sutro Biopharma in Q4 2018 and has held it in 29 quarters since.
  • Vanguard Group's Sutro Biopharma position peaked at $46.4M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.